D.R. Chirovsky
Merck & Co., Inc., Rahway, NJ, USA (United States) · 8 works · 30 citations · h-index 3
Top works
- OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
- Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma
- OA07.04 Overall Survival in Patients with Advanced NSCLC Receiving Taxane-Containing Regimen After Exposure to Immunotherapy and Platinum-Doublet
- 24P: 5-year real-world outcomes with first-line (1L) pembrolizumab plus (+) chemotherapy in advanced/metastatic NSCLC
- 95P Neoadjuvant treatment pattern and association between real-world event-free survival (rwEFS) and overall survival (OS) in patients (pts) with resected early-stage non-small cell lung cancer (eNSCLC)
- 51P Real-word outcomes of immunotherapy in non-small cell lung cancer: A population-based cohort study in Sweden
- EP02.03-009 Real-world Disease-Free Survival as a Predictor of Overall Survival in Resected Early-Stage Non-Small Cell Lung Cancer
- P1.25-06 Real-world Primary Treatment Patterns in Stages I-III Non-Small Cell Lung Cancer